Marco Enea
YOU?
Author Swipe
View article: Stay or go? Exploring physician turnover in European Hospitals–Evidence from the METEOR survey
Stay or go? Exploring physician turnover in European Hospitals–Evidence from the METEOR survey Open
According to the World Health Organization (WHO), in 2022 there was a shortfall of approximately 1.2 million doctors, impacting healthcare system and patient care. Understanding turnover intentions is crucial for managing the healthcare wo…
View article: Impact of First and Further Decompensation in Metabolic-Dysfunction Associated Compensated Advanced Chronic Liver Disease
Impact of First and Further Decompensation in Metabolic-Dysfunction Associated Compensated Advanced Chronic Liver Disease Open
BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) currently stands as one of the foremost global health challenges, with a prevalence of 38% worldwide according to the most recent estimates [1] and with a concerni…
View article: Health Literacy, Diet, and Lifestyles for the Promotion of Health and Empowerment of University Students and Staff: The “ALFADIET” Study
Health Literacy, Diet, and Lifestyles for the Promotion of Health and Empowerment of University Students and Staff: The “ALFADIET” Study Open
Introduction Appropriate nutrition and healthy lifestyles are key elements in the prevention of non-communicable diseases and in promoting individual well-being. In this context, health and digital literacy are essential tools to foster pe…
View article: Sleep Disorders, Smartphone Use and Mental Health: A Cross-Sectional Study on a Sample of Students from the University of Palermo – MORPHEO
Sleep Disorders, Smartphone Use and Mental Health: A Cross-Sectional Study on a Sample of Students from the University of Palermo – MORPHEO Open
Introduction Sleep disorders constitute a significant public health concern recognized by the World Health Organization (WHO) in the ICD (International Classification of Diseases), with notable implications for young populations. Research …
View article: Modelling Nurses’ Intention to Leave the Hospital and the Profession using a Bivariate Additive Ordered Model via Penalized Likelihood with the R Package Pblm
Modelling Nurses’ Intention to Leave the Hospital and the Profession using a Bivariate Additive Ordered Model via Penalized Likelihood with the R Package Pblm Open
IntroductionAddressing the shortage of healthcare workers requires a clear understanding of the factors associated with nurses’ intention to leave their current hospital (ITL1), or more critically, to leave the healthcare profession altoge…
View article: Impact of first and further decompensation in patients with compensated ACLD due to MASLD
Impact of first and further decompensation in patients with compensated ACLD due to MASLD Open
In this large international multicenter cohort of 6,061 patients with compensated advanced chronic liver disease (cACLD) due to metabolic dysfunction-associated steatotic liver disease (MASLD), we examined the clinical impact of first and …
View article: A Markov Model Unveiling the Impact of Resmetirom on the Natural History of <scp>MASLD</scp> Patients: A Sistematic Review and Meta‐Analysis
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of <span>MASLD</span> Patients: A Sistematic Review and Meta‐Analysis Open
Background and Aim The MAESTRO‐NASH phase 3 trial reported that a 52‐week treatment of Resmetirom is effective in improving fibrosis and metabolic dysfunction‐associated steatohepatitis (MASH) in patients with MASH and F2 or F3 fibrosis, w…
View article: Supplementary Table 2 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Supplementary Table 2 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death Open
Supplementary Table 2. Patient characteristics at baseline.
View article: Supplementary Table 1 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Supplementary Table 1 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death Open
Supplementary Table 1. Representativeness of Study Participants.
View article: Supplementary Table 3 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Supplementary Table 3 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death Open
Supplementary Table 3. Rates of HCC radiological progression or clinical hepatic decompensation as first event.
View article: Supplementary Figure S1 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Supplementary Figure S1 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death Open
Supplementary Figure S1. Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with systemic therapy at highest risk of death. Clinical hepatic decompensation is associated with higher hazard ratio for deat…
View article: Data from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Data from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death Open
Purpose:The prognosis of patients with unresectable hepatocellular carcinoma (HCC) and compensated cirrhosis is influenced by cancer progression. Data on the incidence and the prognostic role of clinical hepatic decompensation (CHD) follow…
View article: Supplementary Table 4 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Supplementary Table 4 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death Open
Supplementary Table 4. Full multivariable model of baseline predictors of clinical hepatic decompensation and HCC progression by competing risks analysis.
View article: Supplementary Table S5 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Supplementary Table S5 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death Open
Supplementary Table S5. Full multivariable model of baseline predictors of clinical hepatic decompensation and HCC progression by competing risks analysis, with albumin-bilirubin (ALBI) included as continuous variable.
View article: Evolution of Hospitalisation Due to Stroke in Italy Before and After the Outbreak of the COVID-19 Epidemic: A Population-Based Study Using Administrative Data
Evolution of Hospitalisation Due to Stroke in Italy Before and After the Outbreak of the COVID-19 Epidemic: A Population-Based Study Using Administrative Data Open
Background/Objectives: Stroke is a leading cause of mortality and disability worldwide, ranking as the second most common cause of death and the third in disability-adjusted life-years lost. Ischaemic stroke, which constitutes the majority…
View article: What is the benefit of prophylaxis to prevent <scp>HBV</scp> reactivation in <scp>HBsAg</scp>‐negative anti‐<scp>HBc</scp>‐positive patients? Meta‐analysis and decision curve analysis
What is the benefit of prophylaxis to prevent <span>HBV</span> reactivation in <span>HBsAg</span>‐negative anti‐<span>HBc</span>‐positive patients? Meta‐analysis and decision curve analysis Open
Background and Aims Patients with overt or occult hepatitis B virus (HBV) infection receiving immunosuppressive treatments have a wide risk of HBV reactivation (HBVr). We performed meta‐analysis with decision curve analyses (DCA) to estima…
View article: Clinical outcomes of <scp>MAFLD</scp> versus <scp>NAFLD</scp>: A meta‐analysis of observational studies
Clinical outcomes of <span>MAFLD</span> versus <span>NAFLD</span>: A meta‐analysis of observational studies Open
Importance The recent change in terminology from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction‐associated fatty liver disease (MAFLD) and metabolic dysfunction‐associated steatotic liver disease (MASLD) highlights the l…
View article: Intention to leave, depersonalisation and job satisfaction in physicians and nurses: a cross-sectional study in Europe
Intention to leave, depersonalisation and job satisfaction in physicians and nurses: a cross-sectional study in Europe Open
The European healthcare sector faces a significant shortage of healthcare workers. Assessing the prevalence of this issue and understanding its direct and indirect determinants are essential for formulating effective recruitment programs a…
View article: Turnover Intention determinants of EU hospital doctors and nurses: results from the METEOR survey
Turnover Intention determinants of EU hospital doctors and nurses: results from the METEOR survey Open
Background To contrast effectively the shortage of healthcare workers in the EU, it is essential to find the determinants of the intention to leave the hospital (ITL) by analyzing the role of burnout (BO), job satisfaction (JS), and other …
View article: Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis Open
Background: Atezolizumab + bevacizumab represent the current standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, direct comparison with other combination treatments including immune checkpoint inh…
View article: Serological status for TORCH in women of childbearing age: a decade-long surveillance (2012–2022) in Italy
Serological status for TORCH in women of childbearing age: a decade-long surveillance (2012–2022) in Italy Open
Introduction. Serological screening and seroprevalence data for TORCH infections represent a key instrument to estimate immunity and vaccination levels and exposure rates to prevent and treat TORCH congenital infections. Hypothesis. Serolo…
View article: Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes Open
Background and Aims: We evaluated the diagnostic accuracy of simple, noninvasive tests (NITs) in NAFLD patients with type 2 diabetes (T2D). Methods and Results: This was an individual patient data meta-analysis of 1780 patients with biopsy…
View article: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis
Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis Open
Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase…
View article: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis
Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis Open
Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase…
View article: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis
Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis Open
Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase…
View article: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis
Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis Open
Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase…
View article: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis
Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis Open
Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase…